ÅǸ޴º
- Àڱ󻸷Áõ, ³°ü³ÀÓ, ½À°ü¼º À¯»ê, ³¼Ò±â´ÉÀúÇÏ, ÀÚ±Ã°æ ¼ö¼ú
[±³¼ö °æ·Â]
¼º±Õ°ü´ëÇб³
°¡Å縯°üµ¿´ëÇб³
´Ü±¹´ëÇб³
Â÷ÀÇ°úÇдëÇб³
[Áø·á °æ·Â]
¼º±Õ°ü´ëÇб³ Á¦ÀϺ´¿ø »êºÎÀΰú
°¡Å縯°üµ¿´ëÇб³ Á¦ÀϺ´¿ø »êºÎÀΰú
´Ü±¹´ëÇб³ Á¦ÀϺ´¿ø »êºÎÀΰú
Â÷ÀÇ°úÇдëÇб³ Â÷ ¿©¼ºÀÇÇבּ¸¼Ò ¼¿ï¿ª Áø·áºÎ¿øÀå
[ÇÐȸ¡¤¿¬±¸¡¤¿¬¼ö¡¤¼ö»ó °æ·Â]
Northwestern University, Feinberg School of Medicine, Chicago
´ëÇÑ°¡Àӷº¸Á¸ÇÐȸ ÆíÁýÀÌ»ç
´ëÇÑ»ý½ÄÀÇÇÐȸ ±³À°À§¿øȸ À§¿ø
Clinical and Experimental Reproductive Medicine (CERM) ºÎÆíÁýÀÎ(2011-2018)
´ëÇÑ»ý½ÄÀÇÇÐȸÁö ºÎÆíÁýÀÎ(2007-2010)
Á¦ 42ȸ Çѱ¹¸ðÀÚº¸°ÇÇÐȸ ÃÖ¿ì¼ö ³í¹®»ó (2017)
Á¦ 61ȸ ´ëÇÑ»ý½ÄÀÇÇÐȸ ¿ì¼ö ³í¹®»ó (2011)
Á¦ 60ȸ ´ëÇÑ»ý½ÄÀÇÇÐȸ ¿ì¼ö Æ÷½ºÅÍ»ó (2010)
[³í¹®]
Early gonadotropin-releasing hormone antagonist protocol in women with polycystic ovary syndrome: A preliminary randomized trial.Shin JJ, Park KE, Choi YM*, ±èÇý¿Á, Choi DH, Lee WS, Cho JH. Clin Exp Reprod Med. 2018 Sep;45(3):135-42.
The likelihood of achieving pregnancy through timed coitus in young infertile women with decreased ovarian reserve. Koo HS, ¼ÛÀοÁ, Â÷¼±È, ¹ÚÂù¿ì, ±èÇý¿Á*. Clin Exp Reprod Med. 2018 Mar;45(1):31-7.
Predictors of live birth and pregnancy success after in vitro fertilization in infertile women aged 40 and over. ±èÇý¿Á, Sung N, ¼ÛÀοÁ*. Clin Exp Reprod Med. 2017 Jun;44(2):111-7.
Serum anti-Mullerian hormone levels decrease after endometriosis surgery. ±è¿µÁÖ, Â÷¼±È, ±èÇý¿Á*. J Obstet Gynaecol. 2017 Apr;37(3):342-6.
¹ÌÈ¥ ¿©¼ºÀÇ ÀӽŴɷ º¸Á¸À» À§ÇÑ ³ÀÚ µ¿°á¿¡ ´ëÇÑ ÀνÄ. Á¶ÇѼ±, ±èÇý¿Á*. J Korean SocMatern Child Health. 2017 Jan;21(1):46-54.
Fertility of patients with polycystic ovary syndrome undergoing in vitro fertilization by age. ȲÀ¯ÀÓ, Â÷¼±È, ¼ÛÀοÁ, ¾ç±¤¹®, ¹ÎÀÀ±â, ±èÇý¿Á*. Int J Gynaecol Obstet. 2016 Oct;135(1):91-5.
Reproductive outcomes of retransferring retained embryos in blastocyst transfer cycles. Yi HJ, ±¸È¼±, Â÷¼±È, ±èÇý¿Á, ¹ÚÂù¿ì, ¼ÛÀοÁ*. Clin Exp Reprod Med. 2016 Jun;43(2):133-8.
The Risk Factors and Pregnancy Outcomes of 48 Cases of Heterotopic Pregnancy from a Single Center. ÀüÁöÇö, ȲÀ¯ÀÓ, Shin IH, ¹ÚÂù¿ì, ¾ç±¤¹®, ±èÇý¿Á*. J Korean Med Sci. 2016 Jul;31(7):1094-9.
A high response to controlled ovarian stimulation induces premature luteinization with a negative impact on pregnancy outcomes in a gonadotropin-releasing hormone antagonist cycle. ±¸È¼±, Â÷¼±È, ±èÇý¿Á, ¼ÛÀοÁ, ¹ÎÀÀ±â, ¾ç±¤¹®, ¹ÚÂù¿ì*. Clin Exp Reprod Med. 2015 Dec;42(4):149-55.
Correlation between the Serum Luteinizing Hormone to Folliclestimulating Hormone Ratio and the Anti-Mullerian Hormone Levels in Normo-ovulatory Women. Lee JE, Yoon SH*, ±èÇý¿Á, ¹ÎÀÀ±â. J Korean Med Sci. 2015 Mar;30(3):296-300.
Complete phenotypic and metabolic profiles of a large consecutive cohort of untreated Korean women with polycystic ovary syndrome.Kim JJ, Hwang KR, Choi YM*, Moon SY, Chae SJ, ¹ÚÂù¿ì, ±èÇý¿Á, Choi DS, Kwon HC, Kang BM, Lee BS, Cho SH, Kim TJ, Kim T, Kim MJ, Park HY. Fertil Steril. 2014 May;101(5):1424-30.
Can high serum anti-Mullerian hormone levels predict the phenotypes of polycystic ovary syndrome (PCOS) and metabolic disturbances in PCOS patients? ȲÀ¯ÀÓ, ¼º³ª¿µ, ±¸È¼±, Â÷¼±È, ¹ÚÂù¿ì, ±èÁø¿µ, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °Àμö, ±èÇý¿Á*. ClinExpReprod Med. 2013 Sep;40(3):135-40.
The effectiveness of earlier oocyte retrieval in the case of a premature luteinizing hormone surge on hCG day in in vitro fertilization-embryo transfer cycles.ÃÖ¹ÎÇý, Â÷¼±È, ¹ÚÂù¿ì, ±èÁø¿µ, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °Àμö, ±èÇý¿Á*. ClinExpReprod Med. 2013 Jun;40(2):90-4.
Comparison of assisted reproductive technology outcomes in infertile women with polycystic ovary syndrome: In vitro maturation, GnRH agonist, and GnRH antagonist cycles .ÃÖ¹ÎÇý, À̼±Èñ, ±èÇý¿Á, Â÷¼±È, ±èÁø¿µ, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °Àμö, ¹ÚÂù¿ì* ClinExpReprod Med. 2012 Dec;39(4):166-71. English.
³¼Ò Àڱ󻸷ÁõÀÇ ¼ö¼úÀû Ä¡·á¸¦ ¹ÞÀº ¿©¼ºÀÇ Ç÷Áß Ç׹ķ¯°ü È£¸£¸ó ¿¬±¸.ÀÌÀç¶ó, À̹οµ, ¹ÚÇý¿ø, Â÷¼±È, ¹ÚÂù¿ì, ±èÁø¿µ, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °Àμö, ±èÇý¿Á* Korean J Obstet Gynecol. 2012 Dec;55(12):935-9. Korean.
Serum anti-Mullerian hormone is a better predictor of ovarian response than FSH and age in IVF patients with endometriosis.À¯ÁöÈñ, Â÷¼±È, ¹ÚÂù¿ì, ±èÁø¿µ, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °Àμö, ±èÇý¿Á*. ClinExpReprod Med. 2011 Dec;38(4):222-7.
Laparoscopic management of early primary peritoneal pregnancy: a case report .±¸È¼±, ¹èÁÖ¿¬, °Àμö, ±Ã¹Ì°æ, ±èÇý¿Á, Â÷¼±È, ÃÖ¹ÎÇý, ±èÁö¿µ, ¾ç±¤¹®*. Clin Exp Reprod Med. 2011 Jun;38(2):109-14.
ÁßÁõ Àڱ󻸷ÁõÀÇ ¼ö¼úÀû Ä¡·á ÈÄ Ã¼¿Ü¼öÁ¤ÀÇ °á°ú.¾ç½ÂÇå, ±èÇý¿Á*, ¼º³ª¿µ, ¾ÈÇö¼÷, Ãß¿¬½Ç, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °Àμö. Korean J Obstet Gynecol. 2011 Sep;54(9):517-22.
Serum anti-Mullerian hormone levels as a predictor of the ovarian response and IVF outcomes.ÃÖ¹ÎÇý, À¯ÁöÈñ, ±èÇý¿Á*, Â÷¼±È, ¹ÚÂù¿ì, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °Àμö. ClinExpReprod Med. 2011 Sep;38(3):153-8.
Comparison of mild ovarian stimulation with conventional ovarian stimulation in poor responders.À¯ÁöÈñ, Â÷¼±È, ¹ÚÂù¿ì, ±èÁø¿µ, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °Àμö, ±èÇý¿Á*. Clin Exp Reprod Med. 2011 Sep;38(3):159-63.
Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for in vitro fertilization: A comparative study. Ãß¿¬½Ç, ÇѾֶó, ¾ç½ÂÇå, ¼º³ª¿µ, Â÷¼±È, ±èÇý¿Á, ¹ÚÂù¿ì, ¼ÛÀοÁ, ±Ã¹Ì°æ, °Àμö, ¾ç±¤¹®*. Korean J Obstet Gynecol. 2011 Oct;54(10):599-604. English
Adverse pregnancy outcomes with assisted reproductive technology in non-obese women with polycystic ovary syndrome: a case-control study.ÇѾֶó, ±èÇý¿Á*, Â÷¼±È, ¹ÚÂù¿ì, ±èÁø¿µ, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °Àμö. Clin Exp Reprod Med. 2011 Jun;38(2):103-8.
Age specific serum anti-Mullerian hormone levels in 1,298 Korean women with regular menstruation.À¯ÁöÈñ, ±èÇý¿Á*, Â÷¼±È, ¹ÚÂù¿ì, ¾ç±¤¹®, ¼ÛÀοÁ, ±Ã¹Ì°æ, °Àμö. Clin Exp Reprod Med. 2011 Jun;38(2):93-7.
Non-invasive prenatal detection of achondroplasia using circulating fetal DNA in maternal plasma.ÀÓÁöÇý, ±è¹ÌÁø, ±è½Å¿µ, ±èÇý¿Á, ¼Û¹ÌÁø, ±è¹ÎÇü, ¹Ú¼Ò¿¬, ¾çÀçÇõ, ·ùÇö¹Ì*. Assist Reprod Genet. 2011 Feb;28(2):167-72.
Prediction and prevention of ovarian hyperstimulation syndrome. ±èÇý¿Á, °Àμö*. ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2010 Dec;37(4):293-305. Korean.
³°ü Æó¼â¿¡ ±âÀÎÇÑ ºÒÀÓ È¯ÀÚ¿¡¼ ³°ü °³Åë¼úÀÇ È¿¿ë¼º.¹ÚÂù¿ì, Â÷¼±È, ¾ç±¤¹®, ÇѾֶó, À¯ÁöÈñ, ¼ÛÀοÁ, ±èÇý¿Á, °Àμö, ±Ã¹Ì°æ, ÀÌ°æ»ó*. ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2010 Dec;37(4):321-7.
¸»ÃÊÇ÷¾× ÀÚ¿¬»ìÇؼ¼Æ÷ ºÐȹ ¹× ¼¼Æ÷¿ëÇØ È°¼ºµµ ºÐ¼®À» ÅëÇÑ ½À°ü¼º À¯»ê À§Ç豺ÀÇ Áø´ÜÀû À¯¿ë¼º¿¡ °üÇÑ ¿¬±¸.ÃÖÁö¿µ, Ȳ¼öÁø, ÇѾֶó, À¯ÁöÈñ, ¹Úµ¿¿í, ¹ÚÂù¿ì, ±èÇý¿Á, Â÷¼±È, ±èÁø¿µ, ¼ÛÀοÁ, ±Ã¹Ì°æ, °Àμö, ¾ç±¤¹®*. ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2010 Jun;37(2):115-24.
Àú¼º¼±ÀÚ±ØÈ£¸£¸ó¼º¼±ÀúÇÏÁõ ¿©¼º¿¡¼ º¸Á¶»ý½Ä¼úÀÇÀÓ½ÅÀ².ÇѾֶó, ¹ÚÂù¿ì*, Â÷¼±È, ±èÇý¿Á, ¾ç±¤¹®, ±èÁø¿µ, ±Ã¹Ì°æ, °Àμö, ¼ÛÀοÁ. ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2010 Mar;37(1):49-56.
¹«Á¤ÀÚÁõÀ» º¸ÀÌ´Â ³²¼º°ú Á¤»ó »ý½Ä·ÂÀ» °¡Áø ¿©¼ºÀÇ °¡°è¿¡¼ °üÂûµÈ X ¿°»öüÀÇ Pericentric Inversion. À̺½ÀÌ, ·ùÇö¹Ì, À̹®Èñ, ¹ÚÁÖ¿¬, ±èÁø¿ì, ÀÌÁß½Ä, ±èÇý¿Á, ±è¹ÎÇü, ¹Ú¼Ò¿¬* ´ëÇÑÀÇÇÐÀ¯ÀüÇÐȸÁö. 2008 Dec;5(2):139-44
ºñÆó¼â¼º ¹«Á¤ÀÚÁõ ȯÀÚ¿¡¼ÀÇ °íȯÀÇ Á¶Á÷º´¸®ÇÐÀû Áø´Ü¿¡ µû¸¥ ü¿Ü¼öÁ¤½Ã¼ú °á°úÀÇ ºñ±³¹ÚÂù¿ì, ¼ÁÖÅÂ*, ¹Ú¿ë¼®, ±èÇý¿Á, ¾ç±¤¹®, ±èÁø¿µ, ±Ã¹Ì°æ, °Àμö, ¼ÛÀοÁ ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2008 Dec;35(4):293-301
°ú¹è¶õÀ¯µµ ½Ã Ç÷Áß AMH¿Í ³¼Ò ¹ÝÀÀ¼º°úÀÇ »ó°ü°ü°è:¿¹ÃøÀÎÀڷμÀÇ È¿¿ë¼º¾È¿µ¼±, ±èÁø¿µ*, Á¶¿¬Áø, ±è¹ÎÁö, ±èÇý¿Á, ¹ÚÂù¿ì, ¼ÛÀοÁ, ±Ã¹Ì°æ, °Àμö ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2008 Dec;35(4):309-17
Àú¹ÝÀÀ±ºÀÇ Ã¼¿Ü¼öÁ¤¿¡¼ ÇÑ °³ÀÇ ¹è¾ÆÀÌ½Ä ½Ã Àӽſ¡ ¿µÇâÀ» ÁÖ´Â ¿äÀÎ ±èÇý¿Á, ±è¹ÎÁö, ¿¬¸íÁø, Â÷¼±È, ±Ã¹Ì°æ, ¼ÛÀοÁ* ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2008 Sep;35(3):213-221
³¼ÒÀÇ ±â´ÉÀÌ ÀúÇÏµÈ ºÒÀÓ È¯ÀÚ¿¡¼ ¿¬·É ¹× ±âÀú Ç÷Áß FSH ¼öÄ¡°¡ ü¿Ü¼öÁ¤½Ã¼úÀÇ ¿¹ÈÄ¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ °üÇÑ ¿¬±¸À¯¿µ, ±è¹ÎÁö, Á¶¿¬Áø, ¿¬¸íÁø, ¾È¿µ¼±, Â÷¼±È, ±èÇý¿Á, ¹ÚÂù¿ì, ±èÁø¿µ, ¼ÛÀοÁ, ±Ã¹Ì°æ, °Àμö, ÀüÁ¾¿µ, ¾ç±¤¹®* ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2007 Sep;34(3):189-96
Outcomes of Controlled Ovarian Hyperstimulation/In Vitro fertilization for Infertile Patients with Borderline Ovarian Tumor after Conservative Treatment.¹ÚÂù¿ì, ¾ç±¤¹®*, ±èÇý¿Á, È«¼º¶õ, ±èÅÂÁø, ÀÓ°æÅÃ, À̱âÇå, °Àμö J Korean Med Sci. 2007 Sep;22(Suppl):S134-S138
Àú¹ÝÀÀ±ºÀÇ Ã¼¿Ü¼öÁ¤À» À§ÇÑ °ú¹è¶õÀ¯µµ¿¡ ÀÖ¾î GnRH Antagonist ¿ä¹ý°ú GnRH Agonist Flare Up ¿ä¹ýÀÇ È¿¿ë¼º¿¡ °üÇÑ ¿¬±¸¾È¿µ¼±, ¿¬¸íÁø, Á¶¿¬Áø, ±è¹ÎÁö, °Àμö, ±Ã¹Ì°æ, ±èÁø¿µ, ¾ç±¤¹®, ¹ÚÂù¿ì, ±èÇý¿Á, Â÷¼±È, ¼ÛÀοÁ* ´ëÇÑ»ý½ÄÀÇÇÐȸÁö. 2007 Jun;34(2):125-131
Expression of CD44s, vascular endothelial growth factor, matrix metalloproteinase-2 and Ki-67 in peritoneal, rectovaginal and ovarian endometriosis ±èÇý¿Á, ¾ç±¤¹®, °Àμö, ±Ã¹Ì°æ, Kim HS, Zhang X, ±èÀμ±* J Reprod Med. 2007 Mar;52(3):207-13
ü¿Ü¼öÁ¤½Ã¼ú½Ã °æÁõÀÇ Àڱ󻸷Áõ°ú ¿øÀκҸíÀÇ ºÒÀÓ ¿©¼ºÀÇ ºñ±³ ±èÇý¿Á, ¹ÚÂù¿ì, ¼ÛÀοÁ, ±Ã¹Ì°æ* ´ëÇÑ»êºÎÀΰúÇÐȸÀâÁö. 2007 Feb;50(2):322-328
Àڱ󻸷ÁõÀÌ ÀÖ´Â ºÒÀÓ ¿©¼º¿¡¼ Áߵ¿¡ µû¸¥ ü¿Ü¼öÁ¤ÀÇ °á°ú ºñ±³ ±èÇý¿Á, °Àμö* ´ëÇѺÒÀÓÇÐȸÁö. 2006 Dec;33(4):219-227
ü¿Ü¼öÁ¤À¸·Î ÀÓ½ÅµÈ ½Öžƿ¡¼ ¼öÁ¤¹æ¹ý¿¡ µû¸¥ ÀӽŠÁß±â triple testÀÇ ÀÇÀÇ ±èÇý¿Á, ¼ÛÀοÁ*, Â÷¼±È, ÇÑÁ¤·Ä, ½ÅÁß½Ä, °Àμö, ±Ã¹Ì°æ ´ëÇÑ»êºÎÀΰúÇÐȸÁö. 2006 Nov;49(11):2341-2346
37¼¼ ÀÌ»óÀÇ È¯ÀÚ¿¡¼ ü¿Ü¼öÁ¤ ½Ã¼ú½Ã GnRH Agonist ÁÖ±â¿Í GnRH Antagonist ÁÖ±âÀÇ ºñ±³ ¿¬±¸.¹ÚÂù¿ì, Â÷¼±È, ±èÇؼ÷, ±èÇý¿Á, ¾ç±¤¹®, ±èÁø¿µ, ¼ÛÀοÁ, À¯±ÙÀç, °Àμö, ±Ã¹Ì°æ* ´ëÇѺÒÀÓÇÐȸÁö. 2005 Sep;32(3):261-8.
°è·ùÀ¯»ê ȯÀÚ¿¡¼ Àڱà °æÀ» ÅëÇÑ À¯»ê¾Æ °üÂûÀÇ Áø´ÜÀû À¯¿ë¼º¿¡ °üÇÑ ¿¬±¸ ¾ç±¤¹®, Â÷¼±È, ±èÈñ¼÷, ±èÁø¿µ, ±èÇý¿Á, ¾ÈÇö°æ, ÃÖÁؽÄ, ·ùÇö¹Ì, °Àμö, ±Ã¹Ì°æ* ´ëÇÑ»êºÎÀΰúÇÐȸÀâÁö. 2005 Feb;48(2):363-9.
½À°ü¼º À¯»ê ȯÀÚ¿¡¼ Àú¿ë·® ¸é¿ª±Û·ÎºÒ¸° Ä¡·á¿Í ¸»ÃÊÇ÷¾× ³» Natural Killer (NK) ¼¼Æ÷ÀÇ ÀÓ°èÄ¡¿¡ °üÇÑ ¿¬±¸ Â÷¼±È, ±èÇؼ÷, ±èÇý¿Á, ¼ÛÀοÁ, À¯±ÙÀç, ±Ã¹Ì°æ, °Àμö, ¾ç±¤¹®* ´ëÇѺÒÀÓÇÐȸÁö. 2005 Sep;32(3):217-22.
Ŭ·Î¹ÌÆæ¿¡ ºÎÀûÀýÇÑ ¹ÝÀÀÀ» º¸ÀÌ´Â ´Ù³¶¼º ³¼Ò ÁõÈıº ȯÀÚ¿¡¼ Aromatase InhibitorÀÇ À¯¿ë¼º ±èÇý¿Á*, ¾ç±¤¹®, Çã°É, ¹ÚÂù¿ì, Â÷¼±È, ±èÇؼ÷, ±èÁø¿µ, ¼ÛÀοÁ, ±Ã¹Ì°æ´ëÇѺÒÀÓÇÐȸÁö. 2005 Mar;32(1):27-32.
º¸Á¶»ý½Ä¼ú¿¡¼Àú¿ë·® Aspirin°ú Prednisolone º´ÇÕÅõ¿©ÀÇ È¿¿ë¼º Çã°É, ¹ÚÂù¿ì, ±èÇý¿Á, ±èÁø¿µ, ¾ç±¤¹®, ±Ã¹Ì°æ*, °Àμö ´ëÇÑ»êºÎÀΰúÇÐȸÁö. 2003 Sep;46(9):1665-1673
HPV 16 ¾ç¼º ÀڱðæºÎ¾Ï¼¼Æ÷ÁÖ¿¡¼Cdna Microarray¿¡ ÀÇÇÑ À¯ÀüÀÚ ¹ßÇö Çã°É, ÀÓÁ¤È, ÀåÇâ¶õ, ¹ÚÂù¿ì, ±èÇý¿Á, Á¶ÁØÇü, °Àμö, ±è¿µ½Ä, ±èÀμ±* ´ëÇÑ»êºÎÀΰúÇÐȸÁö. 2003 Apr;46(4):810-819
µ¿°áº¸Á¸ ¹è¾ÆÀ̽Ŀ¡¼ ºÐºñ±â Àڱ󻸷 À¯µµ½ÃÇÁ·Î°Ô½ºÅ×·Ð Åõ¿© ¹æ¹ý¿¡ µû¸¥ Âø»óÀ²°ú ÀÓ½ÅÀ²ÀÇ ºñ±³ ¹ÚÂù¿ì, Çã°É, ±è¹®¿µ, ¼ÛÇöÁ¤, ±èÇý¿Á, ¾ç±¤¹®, ±èÁø¿µ, ¼ÛÀοÁ, À¯±ÙÀç, õ±¤¿ì, º¯Çý°æ, ±Ã¹Ì°æ, °Àμö* ´ëÇѺÒÀÓÇÐȸÁö. 2003 Sep;30(3):193-202
³°ü ºÒÀÓȯÀÚ¿¡¼ ³°ü °³Åë¼ú½Ã Áø´Üº¹°°æÀÇ È¿¿ë¼º ¹ÚÂù¿ì, ±èÇý¿Á, Çã°É, ¾ç±¤¹®, ±èÁø¿µ, ¼ÛÀοÁ, À¯±ÙÀç, ÀüÁ¾¿µ, ÀÌ°æ»ó, °Àμö, ±Ã¹Ì°æ* ´ëÇѺÒÀÓÇÐȸÁö. 2003 Jun;30(2):141-150
´ÙÅÂÀӽۨ¼ö¼ú(Multifetal Pregnancy Reduction)ÈÄ ¿ÏÀüžƼսǿ¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÎÀÚ ±èÇý¿Á, ±è¹®¿µ, ¼ÛÇöÁ¤, ¹ÚÂù¿ì, Çã°É, ±èÁø¿µ, ¾ç±¤¹®, À¯±ÙÀç, ¼ÛÀοÁ, ÀüÁ¾¿µ, ±Ã¹Ì°æ, °Àμö* ´ëÇѺÒÀÓÇÐȸÁö. 2003 Mar;30(1):39-45
[Áø·á °æ·Â]
[ÇÐȸ¡¤¿¬±¸¡¤¿¬¼ö¡¤¼ö»ó °æ·Â]
[³í¹®]
Copyright ¨Ï chamc, All rights reserved.